<DOC>
	<DOCNO>NCT00780143</DOCNO>
	<brief_summary>This Phase I/II study determine safety , tolerability identify MTD DLT Plitidepsin combination fix dose Cytarabine patient relapsed/refractory leukemia determine response rate combination Plitidepsin Cytarabine patient relapsed/refractory AML treat MTD .</brief_summary>
	<brief_title>Clinical Study Plitidepsin ( Aplidin® ) Combination With Cytarabine Patients With Relapsed/Refractory Leukemia</brief_title>
	<detailed_description>This Phase I/II study determine : - safety , tolerability identify MTD DLT Plitidepsin combination fix dose Cytarabine patient relapsed/refractory leukemia determine response rate combination Plitidepsin Cytarabine patient relapsed/refractory AML treat MTD . - pharmacokinetic parameter Plitidepsin combination Cytarabine . - whether Plitidepsin combination Cytarabine exert antiangiogenic effect measure reduction microvessel density VEGFR-1 expression bone marrow biopsies patient relapsed/refractory leukemia . - whether measurement free serum VEGF level , soluble circulate VEGF Receptor Peripheral Progenitor Endothelial cell provide early marker response Plitidepsin . - effect Plitidepsin Cytarabine cytidine deaminase activity correlate result Cytarabine drug resistance . - change leukemic gene expression result Plitidepsin Cytarabine administration . - tumor response duration . - progression free survival overall survival .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>1 . Patients must cytologically ( flow cytometry ) document relapsed/refractory Acute Myeloid leukemia Acute Lymphoid leukemia standard therapy anticipate result durable remission . Chronic Myeloid leukemia blast crisis progress Gleevec® intolerant Gleevec® FDA approve BCRABL Tyrosine Kinase Inhibitors . Patients untreated AML ALL elect receive standard therapy also eligible . Relapsed/refractory leukemia patient may combination 1 course chemotherapy . In addition , leukemia secondary preexisting hematologic disorder highgrade myelodysplastic syndrome also eligible . 2 . ≥18 year age . 3 . Patients must inform investigational nature study must give write informed consent accordance institutional federal guideline . Patients provide informed consent eligible study . 4 . Prior radiotherapy , chemotherapy biologic therapy allow . Previous line ( ) systemic chemotherapy complete least 2 week prior start protocol treatment . Concurrent hydroxyurea administration allow control WBC count , platelet count , symptom discontinue 24 hour prior first APLIDIN® dose . For patient CML blast crisis , Gleevec® BCRABL Tyrosine Kinase Inhibitors must stop least 7 day prior first APLIDIN® dose . t. 5 . Patients must ECOG performance status ≤2 ( Appendix C ) . 6 . Laboratory data : Serum Total Bilirubin &lt; 1.5 mg/dL X institutional ULN ( except Gilbert syndrome clearly document LFTs normal ) . AST ( SGOT ) /ALT ( SGPT ) /ALKP ≤ 2.5 X institutional ULN . Creatinine clearance &gt; 40 ml/min , calculate accord Cockcroft Gault 's formula ( Appendix D ) . 7 . Negative pregnancy test woman childbearing potential . 8 . Bone Marrow Assessment within two week first Aplidin® administration . 9 . Estimated life expectancy &gt; 1 month . 10 . Left ventricular ejection fraction within normal limit . 1 . Previous treatment Plitidepsin . 2 . Prior autologous and/or allogeneic hematopoietic stem cell transplantation ( HSCT ) patient eligible due high risk toxicity relate treatment procedure . 3 . Active metastatic secondary primary malignancy . 4 . Patients known Central Nervous System involvement exclude clinical trial poor prognosis often develop progressive neurologic dysfunction would confound evaluation neurologic adverse event . 5 . Serious concomitant systemic disorder would compromise safety patient compromise patient 's ability complete study , include follow specific condition : Uncontrolled psychiatric illness medical illness principle investigator feel compromise patient 's tolerance study medication . Significant nonneoplastic liver disease ( e.g. , cirrhosis , active chronic hepatitis ) . Uncontrolled endocrine disease ( e.g . diabetes mellitus , hypothyroidism hyperthyroidism ) ( i.e . require relevant change medication within last month , hospital admission within last 3 month ) . Uncontrolled systemic infection . 6 . Other relevant cardiac condition : History presence unstable angina , myocardial infarction , valvular heart disease congestive heart failure . Previous mediastinal radiotherapy . Uncontrolled arterial hypertension despite optimal medical therapy . Previous treatment doxorubicin cumulative dos excess 400 mg/m² . Any grade cardiac arrhythmia accord CTCAE v3.0 ( see appendix F ) exception &lt; grade 3 supraventricular tachycardia proven response medical condition anemia , fever , etc . his/her underlying leukemia . 7 . History hypersensitivity reaction cremophor , Cytarabine , Mannitol , Plitidepsin ( Aplidin® ) . 8 . Myopathy clinical situation cause significant persistent elevation CK ( &gt; 2.5 ULN two different determination perform one week apart ) . 9 . History significant Cytarabine relate neurotoxicity . 10 . Grade &gt; 2 motor sensory neuropathy cause . 11 . Men woman reproductive potential use effective contraceptive method . The effect Plitidepsin develop human fetus recommend therapeutic dose unknown . For reason , woman childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry , duration study participation 6 month . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . Also , wife female partner male patient become pregnant study , investigator must notify promptly pregnant woman refer appropriate followup Highrisk Obstetrician . 12 . Pregnant and/or lactate woman . 13 . Patients immune deficiency increase risk lethal infection treat marrowsuppressive therapy , therefore , know HIVpositive patient active HIV infection and/or receive combination antiretroviral therapy exclude study possible pharmacokinetic interaction Plitidepsin agent administer study . HIV test require unless infection clinically suspect . 14 . Known active HBV HCV infection . Patients serological evidence current past hepatitis B exposure exclude unless serological finding clearly due vaccination . HBV HCV test require unless infection clinically suspect . 15 . Concomitant therapy therapeutic dose coumadin permit . A suboptimal dose permeability venous access device allow . 16 . Treatment investigational product 30 day period inclusion study . Washout period since end precedent therapy le : 6 week nitrosoureas high dose chemotherapy . 2 week chemotherapies biological agent . 4 week radiation radionuclide therapy ( 6 week case prior extensive external beam radiation , 25 % bone marrow distribution ) . 24 hour hydroxyurea . 7 day Gleevec® BCLABL tyrosine Kinase inhibitor . 17 . Limitation patient´s ability comply treatment followup protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Tumor</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Plitidepsin</keyword>
	<keyword>Aplidin</keyword>
</DOC>